L Number	Hits	Search Text	DB	Time stamp
1	44	Vapreotide	USPAT;	2003/12/22
]			EPO; JPO; DERWENT	14:43
2	o	vapreotide same sulfonic	USPAT;	2003/12/22
-		•	EPO; JPO;	14:44
	0	vapreotide same sulfuric	DERWENT	2003/12/22
3		Vapreocide same surruito	USPAT; EPO; JPO;	14:44
1			DERWENT	
4	0	vapreotide same trifluoroacetic	USPAT;	2003/12/22
			EPO; JPO; DERWENT	14:44
5	o	vapreotide same trifluoro	USPAT;	2003/12/22
ĺ		_	EPO; JPO;	14:44
6	1159	GnRH	DERWENT USPAT;	2003/12/22
8	1139	GILL	EPO; JPO;	15:01
}			DERWENT	·
7	25	GnRH and azaline	USPAT;	2003/12/22
\ !	!		EPO; JPO; DERWENT	14:45
8	18	(GnRH and azaline) and suspension	USPAT;	2003/12/22
	,	-	EPO; JPO;	14:45
10	10	((GnRH and azaline) and suspension) and	DERWENT USPAT;	2003/12/22
10	10	((GnRH and azaline) and suspension) and acid adj salts	EPO; JPO;	15:35
		_	DERWENT	
9	2	((GnRH and azaline) and suspension) and	USPAT;	2003/12/22
}		acid adj salt	EPO; JPO; DERWENT	14:51
11	59	deghenghi and romano	USPAT;	2003/12/22
} ~~			EPO; JPO;	14:57
		1	DERWENT	0002/12/22
12	2	boutignon and francois	USPAT; EPO; JPO;	2003/12/22
			DERWENT	
13	177	GnRH adj antagonist	USPAT;	2003/12/22
			EPO; JPO; DERWENT	15:22
14	0	(GnRH adj antagonist) adj5 suspension	USPAT;	2003/12/22
]		,	EPO; JPO;	15:01
	4	(6.77 - 1;	DERWENT	2002/12/22
15	1	(GnRH adj antagonist) same suspension	USPAT; EPO; JPO;	2003/12/22
}			DERWENT	{ ```
16	0	(GnRH adj antagonist) adj5 acid adj salts	USPAT;	2003/12/22
}			EPO; JPO; DERWENT	15:02
17	0	GnRH adj antagonist adj5 acid adj salts	USPAT;	2003/12/22
			EPO; JPO;	15:03
1.0	_	d   d	DERWENT	h200 0 3 /1 2 /2 2
18	0	ac-d-nal-dcpa-d-pal-ser-tyr-d-hci-leu-ilys	-pseau;a1a-1   EPO; JPO;	15:30
[			DERWENT	
20	528486	GnRH adj antagonist adj5 peptide and acid	USPAT;	2003/12/22
1		salts	EPO; JPO; DERWENT	15:22
21	2	GnRH adj antagonist adj5 peptide and acid	USPAT;	2003/12/22
	· •	adj salts	EPO; JPO;	15:23
	^	CARU add antagenist addi neutide addi	DERWENT	2003/12/22
22	0	GnRH adj antagonist adj5 peptide adj5 suspension	USPAT; EPO; JPO;	15:23
			DERWENT	
19	23	GnRH adj antagonist adj5 peptide	USPAT;	2003/12/22
[			EPO; JPO; DERWENT	15:24
23	0	Ac-D-Nal-DCpa-D-Pal-Ser-Tyr-D-Hci-Leu-Ilys		H2003/12/22
			EPO; JPO;	15:32
<u></u>	<u> </u>	<u>                                      </u>	DERWENT	<u> </u>

Search History

12/22/03 5:25:51 PM Page 1

24	0	Ac adj D adj Nal adj DCpa adj Pal adj Ser	USPAT;	2003/12/22
23	Ü	adj Tyr adj D adj Hci adj Leu adj Ilys	EPO; JPO;	15:34
		adj Pro adj D adj Ala adj NH2	DERWENT	
25	0		USPAT;	2003/12/22
			EPO; JPO;	15:35
			DERWENT	
26	0	som adj "230"	USPAT;	2003/12/22
			EPO; JPO;	15:35
]			DERWENT	1
27	103	antide	USPAT;	2003/12/22
			EPO; JPO;	15:35
}			DERWENT	1
28	12	antide and acid adj salts	USPAT;	2003/12/22
			EPO; JPO;	] 15:35
1			DERWENT	
29	11	antide and acid adj salts and suspension	USPAT;	2003/12/22
\ \ \			EPO; JPO;	15:36
l i	_		DERWENT	
30	0	(antide and acid adj salts and	USPAT;	2003/12/22
]		suspension) and microcrystalline	EPO; JPO;	15:36
]		],,	DERWENT	]
31	10	(antide and acid adj salts and	USPAT;	2003/12/22
i i		suspension) and crystalline	EPO; JPO;	16:49
33	1	h	DERWENT	0002/20/00
33	1	teverelix and trifluoroacetate	USPAT;	2003/12/22
			EPO; JPO; DERWENT	16:49
32	7	teverelix		2003/12/22
32	,	reveterry	USPAT; EPO; JPO;	17:24
			DERWENT	11.24
34	950	peptide and counterions	USPAT;	2003/12/22
7 3	930	peperde and counterrous	EPO; JPO;	17:24
			DERWENT	1,.54
35	2	peptide adj5 counterions	USPAT;	2003/12/22
[ ]	<b>~</b>	Labores and contractions	EPO; JPO;	17:25
			DERWENT	
36	o i	peptides adi5 counterions	USPAT;	2003/12/22
* *	Ĭ		EPO; JPO;	17:25
\			DERWENT	}